|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Anticyclic citrullinated peptide antibodies (anti-CCP) are considered specific markers of rheumatoid arthritis and have been included in the revised classification criteria for RA diagnosis. However, these antibodies have also been detected in patients with other rheumatological disorders is to identify the prevalence of positive anti-CCP patients in RA and non-RA rhematological diseases, to determine the diagnostic value of anti-CCP for the diagnosis of RA. An observational study was carried out in department of Microbiology at Dr. Ram Manohar Lohia Hospital, New Delhi over a period of 1 year. In 343 RA and 52 other rheumatological disease patients anti-CCP antibodies were determined. Anti-CCP antibodies were detected in 277 of the 395 patients. The prevalence of anti-CCP was 274/373 in RA, 1/4in patients with spondyloarthritis, 1/4 in patients with juvenile rheumatoid arthritis and 1/15 in patients with systemic lupus erythematosus. Anti-CCP are a hallmark of RA, but may be observed in other inflammatory, systemic, or rheumatological diseases.